GlassScriptPhysician profile
Troy Henderson
NPI 1609324003
$18,033.06
in general payments reported to CMS, 2019-2025
58 companies · $2,929 in 2025
The $2,929 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,573 · 2022: $3,341 · 2023: $3,685 · 2024: $4,505 · 2025: $2,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,141.14 |
| Travel and Lodging | $978.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,980.01 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,943.00 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,844.53 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $1,279.28 | 2021-2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,197.32 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $1,189.01 | 2021-2025 | |
| Lilly USA, LLC | $1,025.09 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $1,019.22 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $856.37 | 2021-2025 | |
| Amgen INC. | $770.79 | 2021-2025 | Repatha, Krystexxa, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $565.52 | 2021-2025 | Trintellix |
| Ironwood Pharmaceuticals, INC | $308.23 | 2021-2025 | Linzess |
| Axsome Therapeutics, INC. | $238.06 | 2022-2025 | Auvelity |
| Amarin Pharma, INC. | $222.01 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $213.31 | 2021-2024 | Livalo |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.